Description
Perjeta (Pertuzumab) is a monoclonal antibody medication that specifically targets the HER2 protein. It is used in combination with other medications to treat certain types of breast cancer that overexpress the HER2 protein.
Uses:
Perjeta is used in combination with Herceptin (trastuzumab) and chemotherapy drugs to treat patients with HER2-positive metastatic breast cancer or early stage breast cancer that has a high risk of recurrence.
Storage Conditions:
Perjeta should be stored in a refrigerator between 2-8°C (36-46°F). The medication should not be frozen and should be protected from light.
Mechanism of Action:
Perjeta targets the HER2 protein, which is overexpressed in certain types of cancers, including breast cancer. By binding to the HER2 protein, Perjeta prevents cancer cell growth and promotes cell death.
HOW TO USE:
Perjeta is administered intravenously in a medical setting by a healthcare professional. It is typically given every three weeks, in combination with Herceptin and chemotherapy drugs.
Precautions:
Perjeta has been associated with severe side effects, including heart failure, lung problems, and an increased risk of infection. Patients with pre-existing heart or lung conditions should use Perjeta with caution.
Drug Interactions:
Perjeta may interact with other medications, particularly those that affect the liver or heart. Patients taking any medications that may affect liver or heart function should inform their healthcare provider before taking Perjeta.
Contraindications:
Perjeta is contraindicated in patients with a history of severe hypersensitivity to Pertuzumab or any of the components of the medication. It is also not recommended for use in patients with severe heart conditions.
Overdose:
There is currently no established protocol for Perjeta overdose. Medical attention should be sought immediately if an overdose is suspected.
Adverse Reactions:
Common side effects of Perjeta include diarrhea, nausea, fatigue, hair loss, decreased appetite, and rash. Additionally, it may cause heart problems, lung problems, and an increased risk of infection. Patients should inform their medical provider of any abnormal and persistent symptoms during treatment.
In conclusion, Perjeta is a monoclonal antibody medication that targets the HER2 protein, used in combination with other drugs to treat certain types of breast cancer. It is administered intravenously in a medical setting, typically every three weeks. Patients with pre-existing heart or lung conditions should use Perjeta with caution. Common side effects include diarrhea, nausea, fatigue, and hair loss. Perjeta should be stored in a refrigerator between 2-8°C (36-46°F).
Reviews
There are no reviews yet.